If you have ulcerative colitis and your gastroenterologist has prescribed Entyvio, the practical question is whether UnitedHealthcare will pay for it and what you have to do first. The short answer is that UnitedHealthcare generally covers Entyvio for moderately to severely active ulcerative colitis, but coverage is conditional. It runs through a prior authorization, it depends on your specific plan and benefit type, and approval requires documentation that you meet the plan's clinical criteria. Coverage is never automatic, and the exact tier, copay, and rules vary by the plan you hold. This article explains how UnitedHealthcare structures Entyvio coverage for ulcerative colitis and what tends to drive an approval.
What Entyvio Is and Why It Matters for Coverage
Entyvio, the brand name for vedolizumab, is an integrin receptor antagonist indicated in adults for moderately to severely active ulcerative colitis. It is a humanized monoclonal antibody that binds the alpha-4-beta-7 integrin and blocks migration of memory T-lymphocytes into inflamed gut tissue, which makes it gut-selective rather than broadly immunosuppressive. The standard regimen is 300 mg infused intravenously at weeks 0, 2, and 6, then every eight weeks, and patients who respond can switch to a 108 mg subcutaneous injection every two weeks for maintenance after the early intravenous doses. The route matters for coverage because intravenous infusions usually fall under your medical benefit while the self-injected pen runs through the pharmacy benefit.
Does UnitedHealthcare Cover Entyvio for Ulcerative Colitis?
UnitedHealthcare publishes its own coverage rules, and Entyvio for ulcerative colitis is addressed in them. The intravenous formulation is governed by the UnitedHealthcare Commercial Medical Benefit Drug Policy for Entyvio, which states the drug is "proven and medically necessary" for moderately to severely active ulcerative colitis when specific criteria are met. The subcutaneous pen is handled under a separate UnitedHealthcare pharmacy prior authorization program for subcutaneous vedolizumab. Both documents apply to commercial plans, and both require prior authorization before coverage begins. Whether your particular plan follows these exact rules depends on your benefit design, so the policy that governs you is the one tied to your member ID, which you can confirm through your plan documents or by calling the number on your card.
The Prior Authorization Criteria UnitedHealthcare Typically Requires
For the intravenous form, the medical benefit policy asks for a documented diagnosis of moderately to severely active ulcerative colitis plus one of the following.
History of failure, contraindication, or intolerance to a TNF blocker, an immunomodulator such as azathioprine, or a corticosteroid
Corticosteroid dependence, meaning you cannot taper off steroids without symptoms returning
The policy also requires that Entyvio is dosed according to the FDA label and is not combined with another targeted immunomodulator, and it sets initial authorization at no more than 12 months. The subcutaneous program similarly requires a qualifying diagnosis and no overlapping advanced therapy. These are the criteria as published, and your plan may apply additional utilization rules.
Step Therapy and Where Entyvio Sits on the Formulary
UnitedHealthcare's published intravenous criteria allow approval after failure of a single conventional therapy, including a corticosteroid, which is a lower hurdle than failing multiple biologics first. This aligns with AGA guidance, which lists vedolizumab among higher-efficacy options and supports early use of advanced therapies rather than gradual step-up after 5-aminosalicylate failure. Even so, individual plans can impose their own step therapy, preferred-product rules, or formulary tier placement that the national policy does not capture, and these affect your out-of-pocket cost. Do not assume a specific tier or copay. Pull your plan's formulary, sometimes called a prescription drug list, and look up vedolizumab directly to see how your plan classifies it and what step therapy, if any, applies before Entyvio is covered.
How to Verify Coverage and Strengthen Your Case
The most reliable path is to confirm your own plan's rules before the first infusion. Read the formulary and the relevant Entyvio policy document for your plan, then make sure your gastroenterologist's prior authorization submission documents the clinical picture the criteria ask for. A strong submission shows the diagnosis with disease activity, the prior therapies you tried and how they failed or were not tolerated, and any steroid dependence. Tracking your bleeding, urgency, stool frequency, and treatment history gives your clinician the specific evidence the UnitedHealthcare criteria reward and reduces back-and-forth that delays approval.
What to Do If Entyvio Is Denied
A denial is not the end of the process. Under federal rules you can request an internal appeal, and you generally have 180 days from the denial notice to file it, with the right to an external review by an independent third party if the internal appeal is upheld. The federal external review process applies when a plan continues to deny after internal appeal. Appeals succeed most often when the denial reason is addressed directly, so read the explanation, identify which criterion the plan says is unmet, and have your gastroenterologist supply the missing documentation, often a letter of medical necessity describing your disease severity and prior treatment failures. If the timeline threatens your health, ask for an expedited review.
Conclusion
UnitedHealthcare generally covers Entyvio for moderately to severely active ulcerative colitis, but only through a prior authorization that requires a documented diagnosis and evidence that you failed, could not tolerate, or are dependent on conventional therapy such as corticosteroids or immunomodulators. The route of administration determines whether the medical or pharmacy benefit applies, and the precise tier, copay, and any step therapy depend on the specific plan you hold rather than a single national rule. The two reliable moves are to verify your own plan's formulary and Entyvio policy before treatment starts, and to make sure your treatment history is documented thoroughly so the prior authorization is supported from the first submission. If a denial comes, the federal appeal and external review process gives you a structured path to challenge it.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.